Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer

被引：0
作者：
N Takigawa
K Kiura
Y Segawa
Y Watanabe
H Kamei
T Moritaka
T Shibayama
H Ueoka
K Gemba
T Yonei
M Tabata
T Shinkai
S Hiraki
M Takemoto
S Kanazawa
K Matsuo
M Tanimoto
机构：
[1] Oncology,Department of Hematology
[2] and Respiratory Medicine,Department of Medicine and Thoracic Oncology
[3] Okayama University Graduate School of Medicine,Department of Internal Medicine
[4] Dentistry,Department of Internal Medicine
[5] and Pharmaceutical Sciences & Okayama University Hospital,Department of Pulmonary Medicine
[6] National Hospital Organization,Department of Pulmonary Medicine
[7] Shikoku Cancer Center,Department of Medicine
[8] Okayama Red Cross Hospital,Department of Pulmonary Medicine
[9] Sumitomo Besshi General Hospital,Department of Pulmonary Medicine
[10] Ehime Prefectural Central Hospital,Department of Radiology
[11] National Hospital Organization,Department of Epidemiology and Prevention
[12] Minami-Okayama Medical Center,undefined
[13] National Hospital Organization,undefined
[14] Sanyo Hospital,undefined
[15] Okayama Rosai Hospital,undefined
[16] Okayama Medical Center,undefined
[17] Okayama University Graduate School of Medicine,undefined
[18] Dentistry,undefined
[19] and Pharmaceutical Sciences & Okayama University Hospital,undefined
[20] Aichi Cancer Center Research Institute,undefined
来源：
British Journal of Cancer | 2006年 / 95卷
关键词：
non-small-cell lung cancer; chemotherapy; radiotherapy; second primary cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Long-term cancer survivors risk development of second primary cancers (SPC). Vigilant follow-up may be required. We report outcomes of 92 patients who underwent chemoradiation for unresectable stage III non-small-cell lung cancer, with a median follow-up of 8.9 years. The incidence of SPC was 2.4 per 100 patient-years (95% confidence interval: 1.0–4.9).
引用
收藏
页码：1142 / 1144
页数：2
相关论文
共 92 条
  • [1] Allan JM(2005)Mechanisms of therapy-related carcinogenesis Nat Rev Cancer 5 943-955
  • [2] Travis LB(2006)Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients Ann Oncol 17 473-483
  • [3] Aupérin A(2005)Does the incidence and outcome of brain metastases in locally advanced non-small cell lung cancer justify prophylactic cranial irradiation or early detection? Lung Cancer 49 109-115
  • [4] Le Pechoux C(2005)Second primary tumors involving non-small cell lung cancer: prevalence and its influence on survival Chest 127 1152-1158
  • [5] Pignon JP(2005)Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group J Clin Oncol 23 2955-2961
  • [6] Koning C(1995)Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group Ann Thorac Surg 60 615-622
  • [7] Jeremic B(2001)Second cancers occurring in patients with early stage non-small-cell lung cancer treated with chest radiation therapy alone J Clin Oncol 19 1056-1063
  • [8] Clamon G(2006)Second primary cancers in patients with stage III non-small cell lung cancer successfully treated with chemo-radiotherapy Jpn J Clin Oncol 36 7-11
  • [9] Einhorn L(2003)Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer Br J Cancer 89 795-802
  • [10] Ball D(1995)Incidence of local recurrence and second primary tumors in resected stage I lung cancer J Thorac Cardiovasc Surg 109 120-129
12345678910